You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 62 No. 11, November 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Neurological Review
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on ISI (40)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Multiple Sclerosis/ Demyelinating Disease
 •Diagnosis
 •Alert me on articles by topic

Acute Disseminated Encephalomyelitis

An Update

Til Menge, MD; Bernhard Hemmer, MD; Stefan Nessler, MD; Heinz Wiendl, MD; Oliver Neuhaus, MD; Hans-Peter Hartung, MD; Bernd C. Kieseier, MD; Olaf Stüve, MD, PhD

Arch Neurol. 2005;62:1673-1680.

Acute disseminated encephalomyelitis (ADEM) is a monophasic autoimmune demyelinating disease of the central nervous system that typically follows a febrile infection or a vaccination. Children are predominantly affected. A plethora of viral and bacterial pathogens and a number of vaccinations have been associated with ADEM. Experimental animal studies indicate that both primary and secondary autoimmune responses contribute to central nervous system inflammation and subsequent demyelination. The clinical diagnosis of ADEM is strongly suggested by a close temporal relationship between an infectious incident or an immunization and the onset of leukoencephalopathic neurological symptoms. Paraclinical tests may support the diagnosis. Particularly helpful are acute signs of newly developed extensive, multifocal, subcortical white matter abnormalities on magnetic resonance images of the brain. The cerebrospinal fluid may disclose a mild lymphocytic pleocytosis and elevated albumin levels. Oligoclonal bands are not always present in ADEM and, if so, may be transient. The major differential diagnosis of ADEM is multiple sclerosis. Treatment options for ADEM consist of anti-inflammatory and immunosuppressive agents. In general, the disease is self-limiting and the prognostic outcome favorable. In the absence of widely accepted clinical or paraclinical diagnostic guidelines, a number of recently conducted observational case series have substantially broadened our understanding about the clinical phenotype, diagnosis, and prognosis of ADEM.


Author Affiliations: Department of Neurology, University of San Francisco, San Francisco, Calif (Dr Menge); Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany (Drs Hemmer, Nessler, Neuhaus, Hartung, Kieseier, and Stüve); Hertie Institute for Clinical Brain Research, Department of Neurology, Eberhard-Karls-University, Tübingen, Germany (Dr Wiendl); Department of Neurology, University of Texas Southwestern Medical Center, and Neurology Section, Medical Service, VA North Texas Health Care System, Dallas (Dr Stüve).







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.